Dicerna Pharmaceuticals announced this week that the Japan Patent Office has said it intends to grant a patent on an application covering Dicer-substrate technology exclusively licensed by the company.
The intellectual property — No. 2007-504009 — relates to the Dicer-substrate compositions for reducing mammalian target gene expression, regardless of their specific sequence, the company said.
The application stems from the work of City of Hope researcher John Rossi.